GE Healthcare Announces Preliminary Phase 3 Results for Flutemetamol Met Endpoints

GE Healthcare

today announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology. T he other study, in young healthy volunteers under age 40, had results concordant with the known lack of brain amyloid in this population. Full results of these studies will be presented in the coming months. [18F]Flutemetamol is a GE Healthcare PET imaging agent in development for the detection of beta amyloid.